# A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer

> **NCT04889495** · — · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Non-small Cell Lung Cancer
- Metastatic Colorectal Cancer
- Metastatic Breast Cancer
- Metastatic Kidney Cancer
- Cervical Cancer
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer

## Interventions

- **DRUG:** Zirabev

## Key facts

- **NCT ID:** NCT04889495
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-05-16
- **Primary completion:** 2025-08-16
- **Final completion:** 2025-08-16
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea.
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04889495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04889495, "A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04889495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*